Special Issue

Bromodomains: A New Target Class for Drug Development

Message from the Guest Editors

Bromodomains have enormous potential as targets for novel therapeutic development in cancer. An explosion of interest in these proteins was facilitated by the establishment of small molecule inhibitors with great selectivity and potency both in vitro and in vivo. On the basis of these promising early results, BET inhibitors have entered human clinical investigations for the treatment of different cancers and other diseases (Algahtani et al., 2019). Next-generation compounds targeting BET bromodomains have been generated using proteolysis-targeted chimera (PROTAC) chemistry, in order to induce targeted degradation of BET proteins (Winter et al., 2015). In parallel, further non-BET bromodomains have been identified as targets for novel therapy in cancers and other diseases. This Special Issue will focus on recent advancements in understanding bromodomain function, ranging from structure to function, and identifying opportunities for drug development for this intriguing class of proteins.

Guest Editors

Dr. Jun Qi

Dana-Farber Cancer Insitute, 450 Brookline Ave. Boston, MA 02215, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA

Dr. Adam David Durbin

St. Jude Children's Research Hospital, 262 Danny Thomas Pl., Memphis, TN 38105, USA

Deadline for manuscript submissions

closed (15 November 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/95192

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

